SCHEMBL5657866

SCHEMBL5657866

CCOc1ccccc1NC(=O)OCCCN1CCN(c2ccc(C)nn2)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.47
LMNA P02545 3/20 0.47
THRB P10828 1/20 0.47
KMT2A Q03164 1/20 0.47
POLB P06746 2/20 0.46
TP53 P04637 1/20 0.44
BLM P54132 1/20 0.44
ADRA1D P25100 1/20 0.44
ADRA1A P35348 1/20 0.44
ADRA1B P35368 1/20 0.44
TSHR P16473 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
KDM4E B2RXH2 1/20 0.43
USP2 O75604 1/20 0.43
ALDH1A1 P00352 1/20 0.43
HPGD P15428 1/20 0.43
HSD17B10 Q99714 1/20 0.43
HTR1A P08908 1/20 0.43
HTR2A P28223 1/20 0.43
EPHX2 P34913 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5655982 0.94 MAPT (0.49) MAPTLMNATHRBKMT2APOLB
SCHEMBL5656937 0.91 MAPT (0.47) MAPTLMNATHRBKMT2APOLB
SCHEMBL5656315 0.87 HTR1A (0.47) MAPTPOLBADRA1DADRA1AADRA1B
SCHEMBL5657710 0.86 HTR1A (0.59) TSHRKDM4EUSP2ALDH1A1HSD17B10
SCHEMBL6707387 0.85 HTR4 (0.51) MAPTLMNATHRBKMT2APOLB
SCHEMBL5657183 0.84 DRD2 (0.55) POLBADRA1DADRA1AADRA1BHTR1A
SCHEMBL5657920 0.83 HTR1A (0.47) MAPTLMNAKMT2APOLBADRA1D
SCHEMBL5657766 0.83 HRH3 (0.56) THRBKMT2ATP53KDM4EHTR1A
SCHEMBL5655836 0.83 GAA (0.50) MAPTLMNAKMT2ATSHRTDP1
SCHEMBL5657076 0.83 ADRA1D (0.53) MAPTLMNAKMT2AADRA1DADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058933-A1 Aryl carbamate derivatives, preperation and use thereof CEREP (FR) 2004-03-25 US claimed
US-7238693-B2 Aryl carbamate derivatives, preparation and use thereof CEREP (FR) 2007-07-03 US disclosed
US-7238693-B2 Aryl carbamate derivatives, preparation and use thereof CEREP (FR) 2007-07-03 US disclosed
US-7238693-B2 Aryl carbamate derivatives, preparation and use thereof CEREP (FR) 2007-07-03 US disclosed
US-20040058933-A1 Aryl carbamate derivatives, preperation and use thereof CEREP (FR) 2004-03-25 US disclosed
EP-1362041-A1 ARYL CARBAMATE DERIVATIVES, PREPARATION AND USE THEREOF Cerep (FR) 2003-11-19 EP disclosed
WO-2002068399-A1 ARYL CARBAMATE DERIVATIVES, PREPARATION AND USE THEREOF CEREP (FR) 2002-09-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058933-A1 Aryl carbamate derivatives, preperation and use thereof HTR4, HTR5A, HTR3C MAPT 3644/4885LMNA 1137/4885THRB 739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.